TherapeuticsMD (TXMD) Gains from Sales and Divestitures (2013 - 2025)

TherapeuticsMD has reported Gains from Sales and Divestitures for 8 years, with the latest figure at $5000.0 in Q4 2025.

• For the quarter ending Q4 2025, Gains from Sales and Divestitures fell 28.57% year-over-year to $5000.0; the trailing twelve-month figure through Dec 2025 stood at $5000.0 (down 28.57% YoY), and the FY2025 full-year result was $5000.0, down 28.57% from the prior year.
• Gains from Sales and Divestitures for Q4 2025 stood at $5000.0, roughly flat from $5000.0 in the prior quarter.
• The five-year high for Gains from Sales and Divestitures was $2.0 million in Q3 2021, with the low at $2.0 in Q1 2024.
• Historically, Gains from Sales and Divestitures has averaged $206883.4 across 5 years, with a median of $7000.0 in 2023.
• Annual changes were most pronounced in 2022 — Gains from Sales and Divestitures tumbled 99.61% — and 2025, when it soared 99900.0%.
• TherapeuticsMD's Gains from Sales and Divestitures stood at $34000.0 in 2021, then plunged by 99.61% to $133.0 in 2022, then jumped by 5163.16% to $7000.0 in 2023, then changed by 0.0% to $7000.0 in 2024, then retreated by 28.57% to $5000.0 in 2025.
• The last three Gains from Sales and Divestitures figures came in at $5000.0 (Q4 2025), $5000.0 (Q3 2025), and $5000.0 (Q2 2025), per Business Quant data.